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Introduction
The retinoblastoma tumor suppressor (pRb) is lost by mutation 
or functional inactivation in virtually all human cancer (Burkhart 
and Sage, 2008; Bremner and Zacksenhaus, 2010). Its disruption 
leads to ectopic cell proliferation, apoptotic cell death, and in-
complete differentiation and may cause cancer in many cell 
types (Zacksenhaus et al., 1996; Chen et al., 2004; Mantela et al., 
2005; Jiang et al., 2010). Rb exerts these effects by modulating 
the activity of transcription factors such as activating E2Fs (Chen 
et al., 2009). These E2Fs activate cell cycle progression and 
DNA synthesis genes as well as proapoptotic, BH3-only factors 
that induce mitochondrial outer membrane permeabilization 
(MOMP) and trigger the intrinsic apoptotic machinery (Guo   
et al., 2001; Hershko and Ginsberg, 2004; Ho et al., 2004, 2007). 
Activating E2Fs also induce p53 via ARF and MDM2, various 
apoptogenic factors, and autophagic genes (Nahle et al., 2002; 
Tracy et al., 2007; Polager et al., 2008). pRb is also thought to 
stimulate lineage-specific transcription factors, including MyoD, 
myogenin, and MEF2C (Gu et al., 1993; Schneider et al., 1994; 
Novitch et al., 1999), and sequester inhibitors of differentiation 
such as Id2, HDAC1, EID-1, and RBP2 (Lasorella et al., 2000; 
MacLellan et al., 2000; Puri et al., 2001; Benevolenskaya et al., 
2005). However, given that ectopic proliferation and apoptosis 
precludes differentiation, the exact role for pRb in differentiation 
remains ill defined. In this study, we addressed the function of 
Rb during myogenesis by uncoupling its effect on cell survival 
or proliferation from its effect on differentiation.
Results and discussion
Rb deficiency during myogenic 
differentiation induces autophagy
To identify cell-autonomous functions of pRb during skeletal 
myogenesis, we analyzed the differentiation of primary Rb
/ 
T
he retinoblastoma tumor suppressor (pRb) is thought 
to orchestrate terminal differentiation by inhibiting 
cell  proliferation  and  apoptosis  and  stimulating   
lineage-specific transcription factors. In this study, we 
show that in the absence of pRb, differentiating primary 
myoblasts fuse to form short myotubes that never twitch and 
degenerate via a nonapoptotic mechanism. The shortened 
myotubes exhibit an impaired mitochondrial network, 
mitochondrial perinuclear aggregation, autophagic deg-
radation, and reduced adenosine triphosphate produc-
tion. Bcl-2 and autophagy inhibitors restore mitochondrial 
function and rescue muscle degeneration, leading to for-
mation of long, twitching myotubes that express normal 
levels of muscle-specific proteins and stably exit the cell 
cycle. A hypoxia-induced glycolytic switch also rescues 
the myogenic defect after either chronic or acute inacti-
vation of Rb in a hypoxia-inducible factor-1 (HIF-1)–
dependent manner. These results demonstrate that pRb is 
required to inhibit apoptosis in myoblasts and autophagy 
in myotubes but not to activate the differentiation pro-
gram, and they also reveal a novel link between pRb and 
cell metabolism.
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to control littermates (n = 3; Fig. 1, G and H). As control, trans-
duction of a constitutively active, phosphomutant pRb (Ad.Rb
K11; 
Jiang and Zacksenhaus, 2002) prevented collapse of Rb
/ myo-
tubes (not depicted) and, concomitantly, the accumulation of 
LC3-II by 1.8-fold (n = 7; P = 0.005; Fig. 1, I and J).
Rb deficiency during myogenic 
differentiation induces mitochondrial  
loss via autophagy
To detect mitochondria, we used MitoTracker, a live cell probe 
that accumulates in mitochondria with intact membrane potential. 
In control myotubes, MitoTracker revealed a uniform, netlike dis-
tribution of mitochondria throughout the cytoplasm (Fig. 2 A, 
top left). In contrast, at DM-2, Rb
/ myotubes exhibited strong 
perinuclear  MitoTracker-positive  aggregates  and  relatively 
sparse cytosolic staining (Fig. 2 A, bottom left). On average, 
70%  of  Rb
/  myotubes  contained  perinuclear  aggregates 
compared with <10% control myotubes (P < 0.001; Fig. 2 B). 
Cytochrome c also exhibited differential staining: it exhibited 
uniform distribution throughout control myotubes but irregular 
punctate/perinuclear staining in Rb
/ myotubes (Fig. S1 C).   
To determine whether mitochondria accumulated within auto-
phagosomes in Rb
/ myotubes, we performed double staining 
with MitoTracker and LC3 antibody in the presence of chloro-
quine. Control myotubes contained very few cytoplasmic ag-
gregates that stained positive for both MitoTracker and LC3 
(Fig. 2 C, left). In contrast, 70% of Rb
/ myotubes contained 
large perinuclear aggregates that stained positive for both mark-
ers (Fig. 2 C, middle). The level of overlap between LC3 and 
MitoTracker was 3.4-fold higher in the entire myotube popula-
tion and fivefold higher in the 70% fraction of Rb
/ myotubes 
that exhibited perinuclear mitochondrial aggregation (Fig. 2 D). 
EM analysis revealed overall reduced mitochondrial content and 
2.2-fold increase in perinuclear accumulation of mitochondria in 
the entire Rb
/ myotube population relative to control (Fig. 2 E). 
Some whole or partially degraded mitochondria engulfed by 
membrane,  representing  autophagosomes  and  autolysosomes 
(Mizushima et al., 2010), were observed around nuclei (Fig. 2 E, 
asterisk) and in cytosol (Fig. S1 D). Consistent with these re-
sults, there was a 20% reduction in mitochondrial to nuclear 
DNA ratio, as determined by real-time PCR (Amthor et al., 2007), 
in Rb
/ versus control cultures at DM-2 (P < 0.001; Fig. 2 F) and 
a 50% reduction in E16.5 limb muscle (P = 0.009; Fig. 2 G). 
Moreover, there was a 20% decrease in ATP level in Rb
/ myo-
tube cultures (not depicted) and a 3.2-fold reduction in ATP 
level in E16.5 limb muscle relative to control (n = 3, P = 0.011; 
Fig. 2 H). The observed difference between the in vitro and in 
vivo results likely reflects the fact that in vitro cultures contain a 
smaller ratio of myotubes/unfused cells than skeletal muscle.
Inhibition of autophagy rescues Rb 
differentiation defect
The aforementioned results prompted us to ask whether inhibi-
tion of cell death or autophagy would rescue Rb
/ myotube 
degeneration. Strikingly, adenovirus-mediated transduction of the 
survival factor Bcl-2, which inhibits both apoptosis and autoph-
agy (Pattingre and Levine, 2006), rescued the differentiation   
myoblasts isolated from limb muscles of embryonic day (E) 
16.5 mini-Rb gene (mgRb):Rb
/ fetuses. These mutant em-
bryos harbor an mgRb that directs Rb expression to the placenta 
and nervous system but not muscles, thereby extending the life 
span of Rb
/ embryos, which otherwise die at E13.5–14.5, to 
birth (Zacksenhaus et al., 1996; Jiang et al., 2001; unpublished 
data). In mgRb:Rb
/ fetuses, myotubes are initially formed at 
E14.5–15.5 and express early muscle–specific markers, but they 
continue to synthesize DNA, fail to express late markers, and 
degenerate (Zacksenhaus et al., 1996; Jiang et al., 2000). As ex-
pected, primary myoblasts derived from mgRb:Rb
/ muscles 
were devoid of pRb (Fig. 1 A).
When confluent cultures of control primary myoblasts were 
incubated in differentiation medium (DM), they spontaneously 
fused to form long multinucleated myotubes that started to twitch 
by day 3–4 and persisted for weeks in culture. Primary Rb
/ 
myoblasts also fused to form short myotubes that contained three 
to six nuclei and expressed near-normal levels of myosin heavy 
chain (MHC; Fig. 1 B and Fig. S1 A). However, at day 3 after dif-
ferentiation (DM-3), these short myotubes degenerated; by day 6, 
virtually all had collapsed (Fig. 1, B and C; and Fig. S1 A). Thus, 
Rb
/ myoblasts underwent abortive differentiation in vitro 
that recapitulated the muscle defects seen in mgRb:Rb
/  
embryos (Zacksenhaus et al., 1996; Jiang et al., 2000).
Cleaved  (activated)  caspase-3  and  cleaved  poly(ADP- 
ribose) polymerase, markers of intrinsic apoptosis, were elevated 
in differentiating Rb
/ cultures relative to control (Fig. S1 B). 
However, TUNEL-positive nuclei were only detected in un-
fused myoblasts but not within myotubes at DM-2 and DM-3 
(Fig. 1 D), indicating that myotube degeneration was not medi-
ated by bona fide apoptotic cell death. Therefore, we asked 
whether degeneration of Rb
/ myotubes was accompanied   
by autophagy, which, depending on the context, can lead to cell 
death or survival (Morselli et al., 2009). During autophagy, bulk 
cytoplasm, including whole organelles, is sequestered in vesi-
cles termed autophagosomes that fuse to lysosomes (forming 
autolysosomes) for degradation (Levine and Kroemer, 2008; 
Narendra  et  al.,  2008;  Mizushima,  2009;  Tolkovsky,  2009; 
Mizushima et al., 2010). To detect autophagy, myoblasts were 
transduced with an adenoviral vector expressing microtubule-
associated protein 1A/1B light chain 3 (LC3) fused to red fluor-
escent protein (Ad.LC3-RFP; Bampton et al., 2005). LC3 
accumulates on autophagosomes as a phosphatidylethanol-
amine (PE)-conjugated form (LC3-II; Mizushima and Yoshimori, 
2007). In control myotubes, LC3 exhibited a diffuse red fluores-
cent pattern (Fig. 1 E, left). In contrast, in Rb
/ myotubes, 
it was detected in perinuclear aggregates (Fig. 1 E, right), indi-
cating autophagosome accumulation.
Autophagosome-bound LC3-II migrates faster than un-
conjugated LC3-I through denaturing protein gels (Mizushima 
and Yoshimori, 2007). At DM-2, LC3-II level was more than 
twofold higher in Rb
/ myotube cultures relative to control 
(n = 3; Fig. 1 F). Chloroquine, an inhibitor of autophagosome–
lysosome fusion, enhanced the level of LC3-II in both Rb
/ 
and control cultures, demonstrating active autophagic flux. We 
also detected a 1.5 ± 0.12-fold (P = 0.016) increase in LC3-II 
expression in E16.5 mgRb:Rb
/ limb muscle (n = 3) relative 293 Hypoxia and autophagy inhibitors rescue the Rb myogenic defect • Ciavarra and Zacksenhaus
Figure 1.  Rb
/ myoblasts transiently differentiate to form short myotubes that do not twitch, express autophagy markers, and slowly degenerate.  
(A) Western blot analysis for pRb in DM-2 cultures. (B) Immunostaining for MHC in DM-3 and DM-6 differentiating myotubes. Nuclei were stained with DAPI 
(blue). (C) Mean number of myotubes on the indicated days after differentiation. Each time point is mean ± SD of six fields from six independent experi-
ments. (D) TUNEL staining. Arrowheads indicate TUNEL-positive nuclei (green). (E) LC3-RFP expression in control (ctrl) and Rb
/ myotubes. Insets show 
nuclear DAPI stain (blue). (F) Representative Western blot (n = 3) for LC3. Chloroquine was added 12 h before cell harvest. (G) Representative Western blot 
for LC3 in E16.5 control and mgRb:Rb
/ muscles. (H) Quantification of LC3-II/tubulin ratio in E16.5 mgRb:Rb
/ skeletal muscles relative to control as 
depicted in G (mean ± SD; n = 3). *, P = 0.016 by Student’s t test. (I) Representative Western blot for LC3-I and LC3-II expression in whole cell lysates from 
the indicated myotubes transduced with Ad.GFP or Ad.RbK11. (J) Quantification of LC3-II/tubulin ratio by Western blots as shown in I. Data represent 
mean ± SD (n = 7). *, P = 0.047; **, P = 0.005 by analysis of variance.JCB • VOLUME 191 • NUMBER 2 • 2010   294
Figure 2.  The Rb
/ muscle defect is characterized by perinuclear mitochondrial/autophagosome aggregates, reduced mitochondrial DNA content, and reduced 
ATP production. (A, left) MitoTracker staining. (right) MitoTracker staining after bezafibrate treatment. (B) Quantification of myotubes with perinuclear MitoTracker-
positive aggregates in untreated (vehicle) or bezafibrate-treated myotubes at DM-2. Data represent mean ± SD (n = 3). *, P < 0.001 by Student’s t test. (C) MitoTracker 
(red) and LC3 immunostaining (green) of myotubes at DM-2. Chloroquine and 3-MA (where indicated) were added 12 h before staining. Note the extensive overlap 
of MitoTracker and LC3 in Rb
/ myotubes (yellow), which is inhibited by 3-MA. (D) Mean percentage of MitoTracker (red) to LC3 (green) overlap in 25 myotubes 
from two independent cultures in control versus Rb
/ myotubes (total) or Rb
/ myotubes with perinuclear mitochondrial aggregation (high). *, P = 7 × 10
5  
by Student’s t test. (E) Ultrastructural analysis of myotubes treated or not with 3-MA at DM-2. Arrowheads point to mitochondria. Asterisks indicate electron-dense 
autolysosomes. N, nucleus. (F) Ratio of mitochondrial DNA/nuclear DNA in the indicated cultures (n = 3). (G) Ratio of mitochondrial DNA/nuclear DNA in E16.5 
skeletal muscle (n = 3; *, P = 0.009). (H) Quantification of ATP in E16.5 skeletal muscle (n = 3; *, P = 0.011). (F–H) Error bars represent SD. *, P < 0.001.295 Hypoxia and autophagy inhibitors rescue the Rb myogenic defect • Ciavarra and Zacksenhaus
Figure 3.  Rescue of Rb-deficient myotube degeneration by Bcl-2 and autophagy inhibitors. (A) Mean number of myotubes per field in indicated myoblast 
cultures induced to differentiate after transduction with Ad.GFP or Ad.Bcl-2. Each point represents the mean ± SD of six fields from six independent experi-
ments. Bcl-2–rescued, twitching Rb
/ myotubes are shown in Video 2. (inset) Western blot for Bcl-2 in Ad.Bcl2-transduced versus uninfected primary myo-
blasts. (B) Immunostaining for MCK (green) in Ad.Bcl-2–transduced control (ctrl) and Rb
/ myotubes at DM-6. (C) Western blot for MCK, myogenin, MHC, 
and troponin T in indicated cultures at DM-6 after transduction with Ad.Bcl-2. Tubulin was used as a loading control. Black lines indicate that intervening 
lanes have been spliced out. (D) Mean number of Rb
/ myotubes after 3-MA treatment, bezafibrate, or DMSO/vehicle as indicated. Counts are mean ± SD   
of six fields (n = 4). (E, left and middle) Brightfield images of the indicated myotubes treated or not with 3-MA at DM-8. (right) Immunostaining for MHC 
(red) at DM-14 in the presence of 3-MA. Arrowheads label 3-MA–rescued Rb
/ myotubes at DM-8. 3-MA–rescued, twitching Rb
/ myotubes are shown 
in Video 4. (F) Immunostaining for BrdU (green) and MHC (red) of 3-MA–treated cultures at DM-2 or DM-10. Rb
/ myotubes incorporated BrdU at DM-2 
(arrowheads) but not DM-10. (G) Brightfield images (left and middle) and MHC staining (right) of the indicated cultures treated or not with bezafibrate. 
Arrowheads point to bezafibrate-rescued Rb
/ myotubes.JCB • VOLUME 191 • NUMBER 2 • 2010   296
Figure 4.  Hypoxia rescues muscle degeneration after chronic or acute inactivation of Rb by inducing glycolysis via HIF-1. (A) Immunostaining for MHC 
(green) in the indicated myoblasts induced to differentiate under normoxia or hypoxia treated or not with lonidamine. Note the shortened myotubes in the 
presence of lonidamine. (B) Representative immunoblot (left) and mean expression of myogenin and MCK normalized for MHC expression (right; n = 3). 
(C) Rb
f/f myoblasts transduced with Ad.GFP or Ad.Cre and immunoblotted for pRb. Tubulin was used as a loading control. (D) Rb
f/f myoblasts transduced 
with Ad.GFP or Ad.Cre and immunostained for pRb (red). (insets) DAPI staining for nuclei (blue). (E) Immunostaining for MHC in Rb
f/f myoblasts transduced 
with Ad.Cre and induced to differentiate in normoxia (top and middle) or hypoxia (bottom). (F, top) Brightfield images of Rb
f/f myoblasts transduced with 
Ad.EV or Ad.Cre and induced to differentiate under hypoxia. (bottom) Larger view of the boxed field. Arrowheads point to rescued Rb
/ myotubes. This 
field is shown in Video 6. (G) Quantification of myotube formation in Rb
f/f myoblasts transduced with Ad.EV or Ad.Cre and induced to differentiate under 
hypoxia. Counts are mean of six representative fields (n = 3). *, P = 0.004. (H) Quantification of myotube formation in the indicated myoblasts induced to 297 Hypoxia and autophagy inhibitors rescue the Rb myogenic defect • Ciavarra and Zacksenhaus
et al., 2005) or dominant-negative Foxo3a (Skurk et al., 2005), 
which inhibit autophagy induced by nutrient or insulin/IGF-1 
deprivation (Mammucari et al., 2007; Zhao et al., 2007), also 
failed to prevent Rb
/ myotube degeneration, although both fac-
tors increased the number and size of control myotubes (Fig. S3, 
A–D). Thus, Foxo3a and mTOR affect survival-associated   
autophagy in response to starvation but not death-associated   
autophagy that accompanies Rb
/ myotube degeneration.
Peroxisome proliferator–activated receptor 
(PPAR) agonist and MOMP antagonist 
rescue the Rb differentiation defect
If mitochondrial loss underlies myotube degeneration in the ab-
sence of pRb, we reasoned that stimulation of mitochondrial 
biogenesis might also rescue the defect. Mitochondrial bio-
genesis is regulated by the coactivator PGC-1 and PPARs, 
which can be activated by bezafibrate, a pan-PPAR agonist (Bastin 
et al., 2008; Wenz et al., 2008). As shown in Fig. 3 (D and G), 
bezafibrate treatment efficiently blocked degeneration of Rb
/ 
myotubes, leading to twitching myotubes that survived for >8 d. 
Longer treatment with bezafibrate became cytotoxic to both 
control and Rb
/ myotubes. Bezafibrate also increased overall 
mitochondrial content, observed by MitoTracker or cytochrome 
c staining (Fig. 2 A, right; and Fig. S1 H), and reduced the per-
centage of myotubes with perinuclear aggregates from 70 to 
40% (P < 0.001; Fig. 2 B). This result is in accord with a recent 
finding that during erythropoiesis, Rb deficiency disrupts mito-
chondrial biogenesis (Sankaran et al., 2008). Next, we assessed 
the effect of blocking MOMP on Rb
/ myotube survival using 
minocycline, an MOMP inhibitor (Zhu et al., 2002). Mino-
cycline treatment delayed the collapse of mutant myotubes, which 
survived and twitched for 8 d (Fig. S3 E). In contrast, transduc-
tion of the x-linked inhibitor of apoptosis (XIAP), which inhib-
its multiple caspases (Ho et al., 2007; Leonard et al., 2007), 
failed to block myotube degeneration (Fig. S3, F and G), indi-
cating that collapse of Rb
/ myotubes can only be effectively 
inhibited before MOMP.
Hypoxia-induced glycolytic shift rescues 
differentiation defect after chronic or acute 
inactivation of Rb
The aforementioned results indicate that during differentiation, 
pRb loss leads to mitochondrial dysfunction and autophagy, re-
duced mitochondrial content and ATP levels, and ultimately 
myotube degeneration. An intriguing possibility is that a meta-
bolic shift from oxidative phosphorylation (OXPHOS) to gly-
colysis would bypass the requirement for mitochondrial function 
and rescue the defect. To test this notion, we investigated the   
effect of hypoxia, which induces such a metabolic shift, on 
myogenic differentiation. A previous study showed that hypoxia 
inhibits the differentiation of immortalized satellite cells, C2C12 
(Di Carlo et al., 2004). However, we found that differentiation 
defect, leading to long multinucleated myotubes that expressed 
MHC and muscle creatine kinase (MCK), and twitched like 
control myotubes for >3 wk in culture (Fig. 3, A and B; and 
Videos 1 and 2). Western blot analysis revealed that myogenin, 
MHC, MCK, and troponin T were undetectable in Rb
/ cultures 
but  expressed  at  comparable  levels  in  Ad.Bcl-2–transduced 
Rb
/ myotubes and control (Fig. 3 C).
Next, we treated cultures with 3-methyladenine (3-MA), 
an inhibitor of a class III phosphatidylinositol 3-kinase, Vps34, 
which is required for nucleation of the autophagic vesicle 
(Levine and Kroemer, 2008). Remarkably, a single dose of 3-MA 
given just before the induction of differentiation prevented 
formation of LC3-positive perinuclear aggregates and peri-
nuclear mitochondrial accumulation (Fig. 2, C and D, right) and 
blocked the degeneration of Rb
/ myotubes, leading to myo-
tubes that twitched for weeks in culture (Fig. 3, D and E; and 
Videos 3 and 4).
The number of myotubes formed was threefold lower after 
3-MA treatment than after Bcl-2 transduction, but the extent of 
twitching was virtually the same (Videos 2 and 4). This is con-
sistent with our observation that Bcl-2 expression increased sur-
vival of both myoblasts and myotubes, whereas 3-MA rescued 
myotube degeneration but increased apoptotic death of unfused 
myoblasts (unpublished data). Thus, different survival path-
ways operate in myoblasts and myotubes, and Rb
/ myotube   
degeneration is cell autonomous, not an indirect consequence 
of high level of death in unfused cells. Adenoviral-mediated 
transduction of a dominant-negative Vps34 allele (Ad.Vps34
dn; 
Trincheri et al., 2008) also rescued the Rb myogenic defect, 
leading to twitching myotubes (Fig. S1 F). Collectively, these 
results indicate that degeneration of Rb
/ myotubes is associ-
ated with autophagy of impaired mitochondria and that inhibi-
tion of this process rescues the Rb myogenic defect.
Rescued Rb
/ myonuclei become  
stably postmitotic
In addition to increased autophagy, DM-2 Rb
/ myotubes also 
exhibited ectopic DNA synthesis (Fig. S1 G; Schneider et al., 
1994; Chen and Wang, 2000). To determine the cell cycle status 
of 3-MA–rescued Rb
/ myotubes, myoblasts were induced to 
differentiate in the presence or absence of 3-MA. After 1 or 9 d, 
the cultures were either maintained in DM or shifted to GM and 
treated with BrdU for 16 h. At DM-2, both 3-MA–treated and 
untreated Rb
/ myotube nuclei but not control myotube nuclei 
labeled positive for BrdU (Fig. 3 F, left). Strikingly, by DM-10, 
3-MA–treated Rb
/ myotubes ceased to incorporate BrdU   
under either DM or GM conditions (Fig. 3 F, right). Thus, rescued 
Rb
/ myotubes can eventually enter a stable postmitotic state.
In contrast to the effect of autophagy inhibitors, suppres-
sion of DNA synthesis with aphidicolin, or cell cycle progres-
sion with p27
kip1, worsened the differentiation defect of Rb
/ 
myoblasts (Fig. S2). Transduction of activated mTOR (Briaud 
differentiate under the indicated conditions. Myotube counts are the mean of six fields (n = 4). (I) MHC staining (red) of the indicated myoblasts transduced 
with Ad.NF-B/HIF-1 and induced to differentiate in normoxia. (J) Quantification of myotube formation in the indicated myoblasts transduced with Ad.EV 
or Ad.NF-B/HIF-1 and induced to differentiate in normoxia. Myotube counts are the mean of six fields (n = 3). Error bars represent SD.
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of primary myoblasts was unaffected. Remarkably, Rb
/ myo-
tubes survived under hypoxic conditions (1% O2), leading to 
long MHC-expressing, twitching myotubes (Fig. 4 A). Immuno-
blotting confirmed high expression of both early (myogenin) 
and late (MCK) markers in hypoxia-rescued Rb
/ myotube 
cultures (Fig. 4 B, left). Densitometry analysis of these factors, 
normalized for MHC expression (i.e., myotube number), re-
vealed that although expression of MCK was near normal, ex-
pression of myogenin was elevated in rescued Rb
/ myotubes 
relative to control, although this was not statistically significant 
(Fig. 4 B, right). When returned to normoxia after 5 d in   
hypoxia, rescued Rb
/ myotubes continued to twitch, once 
again highlighting the transient requirement for Rb function in 
the first few days after differentiation.
To test whether hypoxia could also rescue the Rb myo-
genic defect after acute inactivation of this tumor suppressor, 
we infected embryonic myoblasts from E16.5 Rb
f/f embryos in 
which exon 19 of Rb is flanked by loxP sites with adenovirus 
encoding Cre recombinase (Vooijs et al., 2002; Huh et al., 
2004). We used high multiplicity of infection that deleted Rb
f/f 
in virtually all cells (Fig. 4, C and D). Remarkably, like after 
chronic inactivation, hypoxia rescued the differentiation defect 
after acute inactivation of Rb, leading to long, twitching myo-
tubes that continued to contract even when transferred back to 
normoxia (Fig. 4, E and F; and Videos 5 and 6).
Hypoxia-rescued Rb differentiation defect 
is glycolysis and hypoxia-inducible factor-1 
(HIF-1) dependent
Under low oxygen tension, HIF-1 induces expression of genes 
responsible  for  glucose  influx  and  glycolysis  (Maynard  and 
Ohh, 2007). To determine whether hypoxia rescued Rb
/ myo-
tubes by inducing a glycolytic shift, myoblasts were induced   
to differentiate in hypoxia in the presence of lonidamine, an   
antagonist of hexokinase, which catalyzes the conversion of glu-
cose to glucose 6-phosphate (Pelicano et al., 2006). Beginning 
at DM-2, a relatively low concentration of 50 µM lonidamine 
had little obvious effect on the survival of control myotubes in 
hypoxia (Fig. 4, A and G). In contrast, under hypoxia, mutant 
myoblasts were highly sensitive to this dose of lonidamine, form-
ing only very short myotubes, most of which ultimately de-
generated (Fig. 4, A and G).
Under normoxia, HIF-1 undergoes ubiquitination via 
the von Hippel–Lindau tumor suppressor protein (VHL), lead-
ing to its proteosomal degradation (Maynard and Ohh, 2007). 
To ask whether HIF-1 was responsible for preventing the de-
generation of Rb
/ myotubes in hypoxia, we first used a VHL 
allele that is constitutively active both in normoxia and hy-
poxia (Ad.VHL-T7-HPACGV; Sufan et al., 2009). Expression 
of this allele dramatically reduced survival of Rb
/ myotubes 
under hypoxic conditions (Fig. 4 G, bottom right), implicating 
HIF-1 in mediating rescue of Rb
/ myotubes under low oxy-
gen tension. Next, we tested whether HIF-1 was sufficient   
to prevent Rb
/ myotube degeneration using a constitutively 
active HIF-1 allele, HIF-1/NF-B, where the N terminus of 
HIF-1 is fused to the NF-B transactivation domain (Vincent 
et  al.,  2000).  Transduction  of  Ad.HIF-1/NF-B  rescued   
degeneration of Rb
/ myotubes in normoxia, leading to sta-
ble myotubes for >10 d (Fig. 4, H and I). We conclude that 
Rb
/ myotubes survive in hypoxia because of an HIF-1– 
induced glycolytic shift.
Our results demonstrate that pRb is required for survival 
during terminal myogenesis but not to actively stimulate the 
myogenic differentiation program. Although we do not rule out 
the possibility that interaction of pRb with MyoD may be   
involved in cell cycle exit or survival, the presence of pRb is 
clearly not required for myoblast differentiation in vitro. Our re-
sults are consistent with observations that Rb
/ cells can effi-
ciently contribute to most adult tissues in Rb
/:Rb
+/+ chimeric 
mice (Maandag et al., 1994; Williams et al., 1994; Tracy et al., 
2007). In muscle, Rb
+/+ cells can complement the Rb
/ defect 
after cell fusion. However, in other tissues, it appears that most 
Rb
/ cells are inherently capable of functional differentiation. 
This has direct implications for differentiation-induced therapy 
for Rb mutant cancer cells.
We show that pRb is required during myogenesis to sup-
press mitochondrial destruction. In most Rb
/ cell types, includ-
ing unfused myoblasts, induction of differentiation at low 
mitogens leads to MOMP and apoptotic cell death. In Rb
/ 
myotubes, we suggest that the intrinsic apoptotic machinery is 
inactive and that mitochondrial dysfunction leads to disruption 
of the mitochondrial network, perinuclear aggregation, and 
autophagic degradation. A similar interplay between inhibition 
of caspase-dependent apoptosis and autophagy has been docu-
mented in other contexts (Xue et al., 2001; Shimizu et al., 2004). 
We propose that abortive cell differentiation in Rb
/ cells is 
caused by mitochondrial dysfunction and survival factors that can 
restore  mitochondrial  function  or  redirect  metabolism  toward 
glycolysis can maintain Rb
/ cell survival and differentiation.
A switch from OXPHOS to glycolysis (Dang et al., 2009; 
Vander Heiden et al., 2009) and Rb inactivation (Burkhart and 
Sage, 2008; Bremner and Zacksenhaus, 2010) represents two 
major hallmarks of cancer. Our results indicate that Rb loss leads 
to inappropriate cell division, which is oncogenic, and also to im-
paired mitochondrial function, which promotes cell death. There-
fore, in the context of neoplastic transformation, Rb loss must 
cooperate with mutations that effectively suppress mitochondrial 
damage or autophagy or shift ATP production from OXPHOS to 
glycolysis. Some of the latter mutations may directly induce gly-
colysis, whereas others may cooperate with deregulated E2F to 
transcriptionally activate glycolytic genes (Darville et al., 1995). 
Thus, we have identified a novel role for pRb in maintaining 
mitochondrial integrity that is important for normal differentiation 
and has implications for cancer metabolism.
Materials and methods
Mouse analysis
Experiments were performed in accordance with guidelines of the Canadian 
Council on Animal Care and Animal Ethics Committee (University Health 
Network, Toronto, Ontario, Canada). Mice were genotyped using DNA ex-
tracted from tail biopsies and the following primers: mgRb/Rblox (forward), 
5-ATTTCAGAAGGTCTGCCAAC-3  and  (reverse)  5-AGAGCAGGC-
CAAAAGCCAGGA-3; Rb mutant (forward), 5-AATTGCGGCCGCATCT-
GCATCTTTATCGC-3 and (reverse) 5-GAAGAACGAGATCAGCAG-3; Rb 
wild type (forward), 5-AATTGCGGCCGCATCTGCATCTTTATCGC-3 and 299 Hypoxia and autophagy inhibitors rescue the Rb myogenic defect • Ciavarra and Zacksenhaus
substrate (Thermo Fisher Scientific) and captured by x-ray film. Films were 
digitized using a scanner (Canon). Quantification of Western blots was 
conducted using Photoshop.
Mitochondrial and nuclear DNA quantitative PCR
Mitochondrial DNA copy number was quantified for an 80-bp fragment of 
mouse mitochondrial DNA (primers: forward, 5-GCAAATCCATATTC-
ATCCTTCTCAAC-3; reverse, 5-GAGAGATTTTATGGGTGTAATGCGGTG-3) 
relative to the NADH dehydrogenase (ubiquinone) flavoprotein 1 single-copy 
nuclear gene (GenBank/EMBL/DDBJ accession no. NM_133666) (primers: 
forward,  5-CTTCCCCACTGGCCTCAAG-3;  reverse,  5-CCAAAACCC-
AGTGATCCAGC-3) using quantitative real-time PCR (7900T lightcycler; 
Applied Biosystems).
ATP, MitoTracker red CMXRos, and TUNEL assays
ATP quantification was performed using a luminescence detection system ac-
cording to the manufacturer’s protocol (ATPlite; PerkinElmer). Mitochondria 
membrane potential was detected using MitoTracker red CMXRos according 
to the manufacturer’s protocol (Molecular Probes). For TUNEL, differentiating 
myoblasts on collagen I–coated coverslips were fixed in 3.7% formaldehyde 
for 10 min, washed three times in PBS, permeabilized with 0.3% Triton X-100   
solution, and washed three times in PBS. Subsequently, 30 U TdT (Fermentas) 
was added to 50 µl TUNEL label solution (Roche).
Adenovirus Cre infections
For adenovirus Cre (Ad.cre; Vector Biolabs) infection of Rb
f/f myoblasts, 
cells were transduced at a multiplicity of infection of 1,300. At a lower 
multiplicity of infection (<1,000), some pRb-positive nuclei within myotubes 
were still detected. 48 h after transduction, myoblasts were induced to dif-
ferentiate.  For  all  other  recombinant  adenoviruses,  transduction  was   
performed when cultures were induced to differentiate. The following adeno-
virus vectors were provided by the indicated sources: Ad.Bcl-2 (M. Crescenzi, 
Higher Institute of Health, Rome, Italy), Ad.GFP-LC3 and Ad.RFP-LC3 
(A.M. Tolkovsky, University of Cambridge, Cambridge, England, UK), 
Ad.HIF-1/NF-B  and  Ad.EV  (K.A.  Vincent,  Genzyme  Corporation, 
Framingham, MA), Ad.VHL-T7-HPACGV (M. Ohh, University of Toronto, 
Toronto, Ontario, Canada), Ad.Vps34
DN (D. Murphy, University of Bristol, Bris-
tol, England, UK), Ad.mTOR, Ad.KD.mTOR, and Ad.ca.mTOR (C.J. Rhodes,   
The University of Chicago, Chicago, IL), Ad.FOXO3a and Ad.DN.FOXO3a 
(K. Walsh, Boston University School of Medicine, Boston, MA), Ad.Rb
K11 
and Ad.p27 (D.S. Park, University of Ottawa, Ottawa, Ontario, Canada), 
and Ad.XIAP and anti-XIAP antibody (R.G. Korneluk, University of Ottawa, 
Ottawa, Ontario, Canada).
Brightfield images and videos
Brightfield images and videos were captured at room temperature using 
20× or 40× air objective lenses on a microscope (TE200; Nikon) fitted with 
a charge-coupled device digital camera (Hamamatsu Photonics). Images 
were acquired using imaging software (SimplePCI; Hamamatsu Photonics). 
Photoshop was used to enhance clarity and contrast using same param-
eters for control and experimental samples.
Online supplemental material
Fig. S1 shows characterization of myogenic defects during abortive differ-
entiation of Rb
/ myoblasts. Fig. S2 shows that cell cycle inhibitors aphidi-
colin and p27
Kip1 accelerate the degeneration of Rb
/ myotubes. Fig. S3 
shows differential effects of mTOR, Foxo3, minocycline, and XIAP on differ-
entiation of Rb
/ myoblasts. Video 1 shows twitching control myotubes 
(Ad.Bcl-2 transduced), Video 2 shows twitching Rb
/ myotubes (Ad.Bcl-2 
transduced), Video 3 shows twitching control myotubes (3-MA treated), 
Video 4 shows twitching Rb
/ myotubes (3-MA treated), Video 5 shows 
twitching control Ad.EV-transduced Rb
f/f myotubes (hypoxia), and Video 6 
shows twitching Rb
f myotubes (hypoxia). Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.201005067/DC1.
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(reverse) 5-CCCATGTTCGGTCCCTAG-3; Rb
floxed (Rb18 + Rb19E) (for-
ward), 5-GGCGTGTGCCATCAATG-3 and (reverse) 5-CTCAAGAGCT-
CAGACTCATGG-3. For timed pregnancies, mice were mated overnight, 
and the day of vaginal plug observation was considered E0.5.
Primary myoblast cell cultures
Over 1,000 embryos from >200 timed pregnancies were used in this 
study to generate primary mouse embryonic myoblast cultures. To maintain 
consistency between experiments, primary myoblasts were induced to dif-
ferentiate at passage 2. Myoblasts were isolated from skeletal muscle of 
limbs of E.16.5–17.5 embryos. Tissues were digested for 20 min at 37°C 
in 80 µl solution containing 1.5 U/ml collagenase IV (Sigma-Aldrich), 
2.4 U/ml dispase (Roche), and 5 mM CaCl2 gently triturated and plated 
onto a 60-mm collagen I–coated culture dish. Myoblasts were maintained 
in growth medium (GM), HAM’s-F10 (Lonza) supplemented with 20% FBS 
(PAA), and 2.5 ng/ml basic FGF (Sigma-Aldrich), in a humidified incuba-
tor at 5% CO2 and 37°C. To induce differentiation, myoblasts were rinsed 
once in 1× PBS and shifted to DM, DME, high glucose, and sodium pyru-
vate (Sigma-Aldrich), supplemented with 3% horse serum (PAA; Ho et al., 
2004). Adenoviruses were amplified in 293T cells maintained in DME plus 
10% FBS and penicillin/streptomycin (Sigma-Aldrich). For drug treatment, 
a single dose of 5 mM 3-MA was added upon differentiation. 500 µM 
bezafibrate and 200 µM minocycline were refreshed every other day.   
40 µM chloroquine was added for 12 h before harvesting the cells. Aphidi-
colin was used at 2.5 µg/ml. For hypoxia experiments, confluent myoblast 
cultures were fed DM and transferred hypoxic conditions (1% O2). 50 µM 
lonidamine  (refreshed  every  other  day;  Sigma-Aldrich)  and  Ad.VHL-T7-
HPACGV were added at DM-1.
BrdU DNA synthesis assay
DM-1 myotube cultures were restimulated in GM or maintained in DM sup-
plemented with 20 µM BrdU for 16 h before fixation with 3.7% formalde-
hyde (10 min). Aphidicolin was added 5 h before addition of BrdU for   
16 h. Cultures were permeabilized using 0.3% Triton X-100 for 10 min, treated 
with 2 N HCl for 25 min, and neutralized with two washes of 0.5 M so-
dium borate, pH 8.5, for 5 min. After blocking in 1.0% BSA for 20 min and 
anti-MHC antibody (1:50; Sigma-Aldrich) for 1 h, cells were washed three 
times for 3 min each with PBS. Secondary antibody fluorescein-conjugated 
Alexa Fluor 563 (red; Invitrogen) was used. BrdU was detected using anti-
BrdU antibody conjugated to FITC (Alexa Fluor 488) and diluted as per 
manufacturer’s protocol (BD). Confocal images of 0.5-µm sections were 
captured at room temperature using a 40× or 63× 1.2 NA C Apochromat 
water objective lens using a confocal microscope (LSM510 META; Carl 
Zeiss, Inc.) and acquisition software (AIM 3.2; Carl Zeiss, Inc.). Photoshop 
(CS2; Adobe) was used to overlay images.
Immunofluorescence and EM
500,000 myoblasts were seeded on 22-mm round collagen I–coated cov-
erslips (BD) and induced to differentiate. Cells were fixed in 3.7% formal-
dehyde, permeabilized in 0.3% Triton X-100, and blocked for 20 min in 
1% BSA/PBS at room temperature. The following antibodies and dilutions 
were used: myogenin, 1:10 (F5D; Santa Cruz Biotechnology, Inc.); MHC, 
1:50 (Sigma-Aldrich); MCK, 1:50 (Santa Cruz Biotechnology, Inc.), cyto-
chrome c, 1:50 (clone A-8; Santa Cruz Biotechnology, Inc.). Secondary 
antibodies fluorescein-conjugated Alexa Fluor 563 and 488 (Invitrogen) 
were added for 45 min. Nuclei were counterstained with DAPI (Invitrogen) 
for 10 min and mounted in fluorescent mounting media (Dako). Mitochon-
drial LC3 (red/green) colocalization was conducted with the Colocaliza-
tion plug-in for ImageJ (National Institutes of Health). Electron micrographs 
were captured at 80 kV using a transmission electron microscope (H-7000; 
Hitachi) equipped with an AMT digital camera (Hitachi) at the University of 
Toronto. Image contrast was enhanced using Photoshop.
Western blot analysis
Cells were lysed on ice in K4IP buffer (50 mM Hepes, pH 7.5, 0.1% 
Tween-20, 1 mM EDTA, 2.5 mM EGTA, 150 mM NaCl, 1.0 mM DTT, and 
10% glycerol) containing protease inhibitors (Sigma-Aldrich). The follow-
ing antibodies and dilutions were used for 3 h at room temperature or 
overnight at 4°C: /-tubulin, 1:4,000 (Cell Signaling Technology);   
MHC, 1:200 (Sigma-Aldrich); LC3b, 1:500 (Cell Signaling Technology); 
MCK, 1:200 (Santa Cruz Biotechnology, Inc.); pRb, 1:1,000 (BD); tropo-
nin T-FS, 1:200 (clone c-18; Santa Cruz Biotechnology, Inc.); poly(ADP-ribose) 
polymerase, 1:500 (Cell Signaling Technology); and caspase-3, 1:500 
(Cell Signaling Technology). Secondary antibodies used were HRP-linked anti-
IgG at 1:2,000 (Cell Signaling Technology) for 1.5 h in blocking buffer, and 
HRP activity was detected using SuperSignal West Dura chemiluminescent JCB • VOLUME 191 • NUMBER 2 • 2010   300
and apoptosis during skeletal myogenesis. Dev. Biol. 227:8–41. doi:10 
.1006/dbio.2000.9892
Jiang,  Z.,  Z.  Guo,  F.A.  Saad,  J.  Ellis,  and  E.  Zacksenhaus.  2001. 
Retinoblastoma  gene  promoter  directs  transgene  expression  exclu-
sively to the nervous system. J. Biol. Chem. 276:593–600. doi:10.1074/
jbc.M005474200
Jiang, Z., T. Deng, R. Jones, H. Li, J.I. Herschkowitz, J.C. Liu, V.J. Weigman, 
M.S. Tsao, T.F. Lane, C.M. Perou, and E. Zacksenhaus. 2010. Rb deletion 
in mouse mammary progenitors induces luminal-B or basal-like/EMT   
tumor  subtypes  depending  on  p53  status.  J.  Clin.  Invest.  120:3296– 
3309. doi:10.1172/JCI41490
Lasorella, A., M. Noseda, M. Beyna, Y. Yokota, and A. Iavarone. 2000. Id2 is a 
retinoblastoma protein target and mediates signalling by Myc oncopro-
teins. Nature. 407:592–598. doi:10.1038/35036504
Leonard,  K.C.,  D.  Petrin,  S.G.  Coupland,  A.N.  Baker,  B.C.  Leonard,  E.C. 
LaCasse, W.W. Hauswirth, R.G. Korneluk, and C. Tsilfidis. 2007. XIAP 
protection of photoreceptors in animal models of retinitis pigmentosa. 
PLoS One. 2:e314. doi:10.1371/journal.pone.0000314
Levine, B., and G. Kroemer. 2008. Autophagy in the pathogenesis of disease. 
Cell. 132:27–42. doi:10.1016/j.cell.2007.12.018
Maandag, E.C., M. van der Valk, M. Vlaar, C. Feltkamp, J. O’Brien, M. van Roon,   
N. van der Lugt, A. Berns, and H. te Riele. 1994. Developmental rescue 
of an embryonic-lethal mutation in the retinoblastoma gene in chimeric 
mice. EMBO J. 13:4260–4268.
MacLellan, W.R., G. Xiao, M. Abdellatif, and M.D. Schneider. 2000. A novel 
Rb- and p300-binding protein inhibits transactivation by MyoD. Mol. 
Cell. Biol. 20:8903–8915. doi:10.1128/MCB.20.23.8903-8915.2000
Mammucari, C., G. Milan, V. Romanello, E. Masiero, R. Rudolf, P. Del Piccolo, 
S.J. Burden, R. Di Lisi, C. Sandri, J. Zhao, et al. 2007. FoxO3 controls 
autophagy in skeletal muscle in vivo. Cell Metab. 6:458–471. doi:10 
.1016/j.cmet.2007.11.001
Mantela, J., Z. Jiang, J. Ylikoski, B. Fritzsch, E. Zacksenhaus, and U. Pirvola. 
2005. The retinoblastoma gene pathway regulates the postmitotic state   
of hair cells of the mouse inner ear. Development. 132:2377–2388 
doi:10.1242/dev.01834.
Maynard, M.A., and M. Ohh. 2007. The role of hypoxia-inducible factors in   
cancer. Cell. Mol. Life Sci. 64:2170–2180. doi:10.1007/s00018-007-7082-2
Mizushima, N. 2009. Physiological functions of autophagy. Curr. Top. Microbiol. 
Immunol. 335:71–84. doi:10.1007/978-3-642-00302-8_3
Mizushima, N., and T. Yoshimori. 2007. How to interpret LC3 immunoblotting. 
Autophagy. 3:542–545.
Mizushima, N., T. Yoshimori, and B. Levine. 2010. Methods in mammalian   
autophagy research. Cell. 140:313–326. doi:10.1016/j.cell.2010.01.028
Morselli, E., L. Galluzzi, O. Kepp, J.M. Vicencio, A. Criollo, M.C. Maiuri, 
and G. Kroemer. 2009. Anti- and pro-tumor functions of autophagy. 
Biochim. Biophys. Acta. 1793:1524–1532. doi:10.1016/j.bbamcr.2009 
.01.006
Nahle, Z., J. Polakoff, R.V. Davuluri, M.E. McCurrach, M.D. Jacobson, M. 
Narita, M.Q. Zhang, Y. Lazebnik, D. Bar-Sagi, and S.W. Lowe. 2002. 
Direct coupling of the cell cycle and cell death machinery by E2F. Nat. 
Cell Biol. 4:859–864. doi:10.1038/ncb868
Narendra, D., A. Tanaka, D.F. Suen, and R.J. Youle. 2008. Parkin is recruited se-
lectively to impaired mitochondria and promotes their autophagy. J. Cell 
Biol. 183:795–803. doi:10.1083/jcb.200809125
Novitch, B.G., D.B. Spicer, P.S. Kim, W.L. Cheung, and A.B. Lassar. 1999. pRb 
is required for MEF2-dependent gene expression as well as cell-cycle   
arrest  during  skeletal  muscle  differentiation.  Curr.  Biol.  9:449–459. 
doi:10.1016/S0960-9822(99)80210-3
Pattingre, S., and B. Levine. 2006. Bcl-2 inhibition of autophagy: a new route   
to cancer? Cancer Res. 66:2885–2888. doi:10.1158/0008-5472.CAN- 
05-4412
Pelicano, H., D.S. Martin, R.H. Xu, and P. Huang. 2006. Glycolysis inhibition 
for  anticancer  treatment.  Oncogene.  25:4633–4646.  doi:10.1038/sj 
.onc.1209597
Polager, S., M. Ofir, and D. Ginsberg. 2008. E2F1 regulates autophagy and the 
transcription of autophagy genes. Oncogene. 27:4860–4864. doi:10.1038/ 
onc.2008.117
Puri, P.L., S. Iezzi, P. Stiegler, T.T. Chen, R.L. Schiltz, G.E. Muscat, A. Giordano, 
L. Kedes, J.Y. Wang, and V. Sartorelli. 2001. Class I histone deacetylases 
sequentially interact with MyoD and pRb during skeletal myogenesis. 
Mol. Cell. 8:885–897. doi:10.1016/S1097-2765(01)00373-2
Sankaran, V.G., S.H. Orkin, and C.R. Walkley. 2008. Rb intrinsically promotes 
erythropoiesis by coupling cell cycle exit with mitochondrial biogenesis. 
Genes Dev. 22:463–475. doi:10.1101/gad.1627208
Schneider, J.W., W. Gu, L. Zhu, V. Mahdavi, and B. Nadal-Ginard. 1994. Reversal 
of  terminal  differentiation  mediated  by  p107  in  Rb-/-  muscle  cells. 
Science. 264:1467–1471. doi:10.1126/science.8197461
References
Amthor, H., R. Macharia, R. Navarrete, M. Schuelke, S.C. Brown, A. Otto, T. 
Voit, F. Muntoni, G. Vrbóva, T. Partridge, et al. 2007. Lack of myostatin 
results in excessive muscle growth but impaired force generation. Proc. 
Natl. Acad. Sci. USA. 104:1835–1840. doi:10.1073/pnas.0604893104
Bampton, E.T., C.G. Goemans, D. Niranjan, N. Mizushima, and A.M. Tolkovsky. 
2005. The dynamics of autophagy visualized in live cells: from autopha-
gosome formation to fusion with endo/lysosomes. Autophagy. 1:23–36. 
doi:10.4161/auto.1.1.1495
Bastin, J., F. Aubey, A. Rötig, A. Munnich, and F. Djouadi. 2008. Activation of 
peroxisome proliferator-activated receptor pathway stimulates the mito-
chondrial respiratory chain and can correct deficiencies in patients’ cells 
lacking its components. J. Clin. Endocrinol. Metab. 93:1433–1441. 
doi:10.1210/jc.2007-1701
Benevolenskaya, E.V., H.L. Murray, P. Branton, R.A. Young, and W.G. Kaelin Jr. 
2005. Binding of pRB to the PHD protein RBP2 promotes cellular differ-
entiation. Mol. Cell. 18:623–635. doi:10.1016/j.molcel.2005.05.012
Bremner, R., and E. Zacksenhaus. 2010. Cyclins, Cdks, E2f, Skp2, and more at 
the  first  international  RB  Tumor  Suppressor  Meeting.  Cancer  Res. 
70:6114–6118. doi:10.1158/0008-5472.CAN-10-0358
Briaud, I., L.M. Dickson, M.K. Lingohr, J.F. McCuaig, J.C. Lawrence, and C.J. 
Rhodes. 2005. Insulin receptor substrate-2 proteasomal degradation me-
diated by a mammalian target of rapamycin (mTOR)-induced negative 
feedback down-regulates protein kinase B-mediated signaling pathway in 
beta-cells. J. Biol. Chem. 280:2282–2293. doi:10.1074/jbc.M412179200
Burkhart, D.L., and J. Sage. 2008. Cellular mechanisms of tumour suppres-
sion by the retinoblastoma gene. Nat. Rev. Cancer. 8:671–682. doi:10 
.1038/nrc2399
Chen, T.T., and J.Y. Wang. 2000. Establishment of irreversible growth arrest in 
myogenic differentiation requires the RB LXCXE-binding function. Mol. 
Cell. Biol. 20:5571–5580. doi:10.1128/MCB.20.15.5571-5580.2000
Chen, D., I. Livne-bar, J.L. Vanderluit, R.S. Slack, M. Agochiya, and R. Bremner. 
2004. Cell-specific effects of RB or RB/p107 loss on retinal development 
implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. 
Cancer Cell. 5:539–551. doi:10.1016/j.ccr.2004.05.025
Chen, H.Z., S.Y. Tsai, and G. Leone. 2009. Emerging roles of E2Fs in cancer:   
an exit from cell cycle control. Nat. Rev. Cancer. 9:785–797. doi: 
10.1038/nrc2696
Dang, C.V., A. Le, and P. Gao. 2009. MYC-induced cancer cell energy metabo-
lism and therapeutic opportunities. Clin. Cancer Res. 15:6479–6483. doi: 
10.1158/1078-0432.CCR-09-0889
Darville, M.I., I.V. Antoine, J.R. Mertens-Strijthagen, V.J. Dupriez, and G.G. 
Rousseau. 1995. An E2F-dependent late-serum-response promoter in a 
gene that controls glycolysis. Oncogene. 11:1509–1517.
Di Carlo, A., R. De Mori, F. Martelli, G. Pompilio, M.C. Capogrossi, and A. 
Germani. 2004. Hypoxia inhibits myogenic differentiation through accel-
erated MyoD degradation. J. Biol. Chem. 279:16332–16338. doi:10.1074/
jbc.M313931200
Gu, W., J.W. Schneider, G. Condorelli, S. Kaushal, V. Mahdavi, and B. Nadal-
Ginard. 1993. Interaction of myogenic factors and the retinoblastoma 
protein  mediates  muscle  cell  commitment  and  differentiation.  Cell. 
72:309–324. doi:10.1016/0092-8674(93)90110-C
Guo, Z., S. Yikang, H. Yoshida, T.W. Mak, and E. Zacksenhaus. 2001. Inactivation 
of the retinoblastoma tumor suppressor induces apoptosis protease- 
activating factor-1 dependent and independent apoptotic pathways during 
embryogenesis. Cancer Res. 61:8395–8400.
Hershko, T., and D. Ginsberg. 2004. Up-regulation of Bcl-2 homology 3 (BH3)-
only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279:8627–8634. 
doi:10.1074/jbc.M312866200
Ho, A.T., Q.H. Li, R. Hakem, T.W. Mak, and E. Zacksenhaus. 2004. Coupling of 
caspase-9 to Apaf1 in response to loss of pRb or cytotoxic drugs is cell-
type-specific. EMBO J. 23:460–472. doi:10.1038/sj.emboj.7600039
Ho, A.T., Q.H. Li, H. Okada, T.W. Mak, and E. Zacksenhaus. 2007. XIAP activ-
ity dictates Apaf-1 dependency for caspase 9 activation. Mol. Cell. Biol. 
27:5673–5685.
Huh, M.S., M.H. Parker, A. Scimè, R. Parks, and M.A. Rudnicki. 2004. Rb is   
required for progression through myogenic differentiation but not main-
tenance of terminal differentiation. J. Cell Biol. 166:865–876. doi:10 
.1083/jcb.200403004
Jiang,  Z.,  and  E.  Zacksenhaus.  2002.  Activation  of  retinoblastoma   
protein in mammary gland leads to ductal growth suppression, pre-
cocious  differentiation,  and  adenocarcinoma.  J.  Cell  Biol.  156:185– 
198. doi:10.1083/jcb.200106084
Jiang, Z., P. Liang, R. Leng, Z. Guo, Y. Liu, X. Liu, S. Bubnic, A. Keating, D. 
Murray, P.E. Goss, and E. Zacksenhaus. 2000. E2F1 and p53 are dispensable, 
whereas p21(Waf1/Cip1) cooperates with Rb to restrict endoreduplication 301 Hypoxia and autophagy inhibitors rescue the Rb myogenic defect • Ciavarra and Zacksenhaus
Shimizu, S., T. Kanaseki, N. Mizushima, T. Mizuta, S. Arakawa-Kobayashi, C.B. 
Thompson, and Y. Tsujimoto. 2004. Role of Bcl-2 family proteins in a 
non-apoptotic programmed cell death dependent on autophagy genes. 
Nat. Cell Biol. 6:1221–1228. doi:10.1038/ncb1192
Skurk, C., Y. Izumiya, H. Maatz, P. Razeghi, I. Shiojima, M. Sandri, K. Sato, L. 
Zeng, S. Schiekofer, D. Pimentel, et al. 2005. The FOXO3a transcription 
factor  regulates  cardiac  myocyte  size  downstream  of AKT  signaling. 
 J. Biol. Chem. 280:20814–20823. doi:10.1074/jbc.M500528200
Sufan, R.I., E.H. Moriyama, A. Mariampillai, O. Roche, A.J. Evans, N.M. Alajez, 
I.A. Vitkin, V.X. Yang, F.F. Liu, B.C. Wilson, and M. Ohh. 2009. Oxygen-
independent degradation of HIF-alpha via bioengineered VHL tumour 
suppressor complex. EMBO Mol Med. 1:66–78. doi:10.1002/emmm 
.200900004
Tolkovsky, A.M. 2009. Mitophagy. Biochim. Biophys. Acta. 1793:1508–1515. 
doi:10.1016/j.bbamcr.2009.03.002
Tracy, K., B.C. Dibling, B.T. Spike, J.R. Knabb, P. Schumacker, and K.F. Macleod. 
2007.  BNIP3  is  an  RB/E2F  target  gene  required  for  hypoxia-induced   
autophagy. Mol. Cell. Biol. 27:6229–6242. doi:10.1128/MCB.02246-06
Trincheri, N.F., C. Follo, G. Nicotra, C. Peracchio, R. Castino, and C. Isidoro. 
2008. Resveratrol-induced apoptosis depends on the lipid kinase activity 
of Vps34 and on the formation of autophagolysosomes. Carcinogenesis. 
29:381–389. doi:10.1093/carcin/bgm271
Vander Heiden, M.G., L.C. Cantley, and C.B. Thompson. 2009. Understanding 
the  Warburg  effect:  the  metabolic  requirements  of  cell  proliferation. 
Science. 324:1029–1033. doi:10.1126/science.1160809
Vincent, K.A., K.G. Shyu, Y. Luo, M. Magner, R.A. Tio, C. Jiang, M.A. Goldberg, 
G.Y. Akita, R.J. Gregory, and J.M. Isner. 2000. Angiogenesis is induced 
in  a  rabbit  model  of  hindlimb  ischemia  by  naked  DNA  encoding  an   
HIF-1alpha/VP16 hybrid transcription factor. Circulation. 102:2255–2261.
Vooijs, M., H. te Riele, M. van der Valk, and A. Berns. 2002. Tumor formation   
in mice with somatic inactivation of the retinoblastoma gene in inter-
photoreceptor  retinol  binding  protein-expressing  cells.  Oncogene. 
21:4635–4645. doi:10.1038/sj.onc.1205575
Wenz, T., F. Diaz, B.M. Spiegelman, and C.T. Moraes. 2008. Activation of the 
PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effec-
tively  improves  a  mitochondrial  myopathy  phenotype.  Cell  Metab. 
8:249–256. doi:10.1016/j.cmet.2008.07.006
Williams, B.O., E.M. Schmitt, L. Remington, R.T. Bronson, D.M. Albert, R.A. 
Weinberg, and T. Jacks. 1994.  Extensive contribution  of Rb-deficient 
cells to adult chimeric mice with limited histopathological consequences. 
EMBO J. 13:4251–4259.
Xue, L., G.C. Fletcher, and A.M. Tolkovsky. 2001. Mitochondria are selectively 
eliminated from eukaryotic cells after blockade of caspases during apop-
tosis. Curr. Biol. 11:361–365. doi:10.1016/S0960-9822(01)00100-2
Zacksenhaus, E., Z. Jiang, D. Chung, J.D. Marth, R.A. Phillips, and B.L. Gallie. 
1996. pRb controls proliferation, differentiation, and death of skeletal 
muscle  cells  and  other  lineages  during  embryogenesis.  Genes  Dev. 
10:3051–3064. doi:10.1101/gad.10.23.3051
Zhao, J., J.J. Brault, A. Schild, P. Cao, M. Sandri, S. Schiaffino, S.H. Lecker, and 
A.L. Goldberg. 2007. FoxO3 coordinately activates protein degradation 
by the autophagic/lysosomal and proteasomal pathways in atrophying 
muscle cells. Cell Metab. 6:472–483. doi:10.1016/j.cmet.2007.11.004
Zhu, S., I.G. Stavrovskaya, M. Drozda, B.Y. Kim, V. Ona, M. Li, S. Sarang, A.S. 
Liu, D.M. Hartley, D.C. Wu, et al. 2002. Minocycline inhibits cytochrome 
c release and delays progression of amyotrophic lateral sclerosis in mice. 
Nature. 417:74–78. doi:10.1038/417074a